Diagnostic Performance of Fas Ligand mRNA Expression for Acute Rejection after Kidney Transplantation: A Systematic Review and Meta-Analysis

Heng, Baoli; Ding, Hongwen; Ren, Haolin; Shi, Liping; Chen, Jie; Wu, Xun; Lai, Caiyong; Yu, Ganshen; Xu, Yunjie; Su, Zexuan

doi:10.1371/journal.pone.0165628

Cited by 4 publications

(3 citation statements)

References 51 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Additionally, CTLc expresses the surface molecule Fas-L, which mediates the FasL-Fas-dependent apoptosis in the renal tubular cell and serves as a marker for acute rejection [ 13 , 38 ]. Granzyme B also cleaves Bid, a proapoptotic molecule that binds to the Bax protein of mitochondria and forms a pore in the mitochondrial membrane, leading to the collapse of the membrane polarity, ROS formation and Cytochrome-c release in the cytoplasm to mediate apoptosis in the cell and ROS-dependent cell damage.…”

Section: Discussionmentioning

confidence: 99%

Lower Circulating Cytotoxic T-Cell Frequency and Higher Intragraft Granzyme-B Expression Are Associated with Inflammatory Interstitial Fibrosis and Tubular Atrophy in Renal Allograft Recipients

et al. 2023

View full text Add to dashboard Cite

Background and Objectives: Inflammatory interstitial fibrosis and tubular atrophy (i-IFTA) is an inflammation in the area of tubular atrophy and fibrosis. i-IFTA is poorly associated with graft outcome and associated with infiltration of inflammatory mononuclear cells. A cytotoxic T cell is a granzyme B+CD8+CD3+ T cell, mainly secret granzyme B. Granzyme B is a serine protease that may mediate allograft injury and inflammatory interstitial fibrosis and tubular atrophy (i-IFTA). However, there is no report identifying the association of granzyme B with i-IFTA after a long post-transplant interval. Material and Methods: In this study, we have measured the cytotoxic T-cell frequency with flow cytometry, serum and PBMCs culture supernatants granzyme-B levels with ELISA and intragraft granzyme-B mRNA transcript expression with the RT-PCR in RTRs in 30 patients with biopsy-proven i-IFTA and 10 patients with stable graft function. Result: The frequency of cytotoxic T cells (CD3+CD8+ granzyme B+) in SGF vs. i-IFTA was (27.96 ± 4.86 vs. 23.19 ± 3.85%, p = 0.011), the serum granzyme-B level was (100.82 ± 22.41 vs. 130.32 ± 46.60, p = 0.038 pg/mL) and the intragraft granzyme-B mRNA transcript expression was (1.01 ± 0.048 vs. 2.10 ± 1.02, p < 0.001 fold). The frequency of CD3+ T cells in SGF vs. i-IFTA was (66.08 ± 6.8 vs. 65.18 ± 9.35%; p = 0.68) and that of CD3+CD8+ T cells was (37.29 ± 4.11 vs. 34.68 ± 5.43%; p = 0.28), which were similar between the 2 groups. CTLc frequency was negatively correlated with urine proteinuria (r = −0.51, p < 0.001), serum creatinine (r = −0.28, p = 0.007) and eGFR (r = −0.28, p = 0.037). Similarly, the PBMC culture supernatants granzyme-B level was negatively correlated with urine proteinuria (r = −0.37, p < 0.001) and serum creatinine (r = −0.31, p = 0.002), while the serum granzyme-B level (r = 0.343, p = 0.001) and intragraft granzyme-B mRNA transcript expression (r = 0.38, p < 0.001) were positively correlated with proteinuria. Conclusions: A decrease in the CTLc frequency in circulation and an increased serum granzyme-B level and intragraft granzyme-B mRNA expression shows that cytotoxic T cells may mediate the allograft injury in RTRs with i-IFTA by releasing granzyme B in serum and intragraft tissue.

show abstract

Section: Discussionmentioning

confidence: 99%

Lower Circulating Cytotoxic T-Cell Frequency and Higher Intragraft Granzyme-B Expression Are Associated with Inflammatory Interstitial Fibrosis and Tubular Atrophy in Renal Allograft Recipients

et al. 2023

View full text Add to dashboard Cite

show abstract

“…The data analysis was performed by STATA version 13.1 (Stata Corporation, College Station, TX, USA) with the midas and metandi modules as well as Meta-Disc 1.4 (XI Cochrane Colloquium, Barcelona, Spain), which were widely used for meta-analysis of diagnostic studies [ 27 , 28 ]. RevMan 5.3 (Cochrane Collaboration, Oxford, UK) was used to do the QUADAS-2 assessment.…”

Section: Methodsmentioning

confidence: 99%

Effectiveness of urine fibronectin as a non-invasive diagnostic biomarker in bladder cancer patients: a systematic review and meta-analysis

Fan

Shen

et al. 2018

World J Surg Onc

View full text Add to dashboard Cite

BackgroundPrevious researches pointed out that the measurement of urine fibronectin (Fn) could be a potential diagnostic test for bladder cancer (BCa). We conducted this meta-analysis to fully assess the diagnostic value of urine Fn for BCa detection.MethodsA systematic literature search in PubMed, ISI Web of Science, EMBASE, Cochrane library, and CBM was carried out to identify eligible studies evaluating the urine Fn in diagnosing BCa. Pooled sensitivity, specificity, and diagnostic odds ratio (DOR) with their 95% confidence intervals (CIs) were calculated, and summary receiver operating characteristic (SROC) curves were established. We applied the STATA 13.0, Meta-Disc 1.4, and RevMan 5.3 software to the meta-analysis.ResultsEight separate studies with 744 bladder cancer patients were enrolled in this meta-analysis. The pooled sensitivity, specificity, and DOR were 0.80 (95%CI = 0.77–0.83), 0.79 (95%CI = 0.73–0.84), and 15.18 (95%CI = 10.07–22.87), respectively, and the area under the curve (AUC) of SROC was 0.83 (95%CI = 0.79–0.86). The diagnostic power of a combined method (urine Fn combined with urine cytology) was also evaluated, and its sensitivity and AUC were significantly higher (0.86 (95%CI = 0.82–0.90) and 0.89 (95%CI = 0.86–0.92), respectively). Meta-regression along with subgroup analysis based on various covariates revealed the potential sources of the heterogeneity and the detailed diagnostic value of each subgroup. Sensitivity analysis supported that the result was robust. No threshold effect and publication bias were found in this meta-analysis.ConclusionsUrine Fn may become a promising non-invasive biomarker for bladder cancer with a relatively satisfactory diagnostic power. And the combination of urine Fn with cytology could be an alternative option for detecting BCa in clinical practice. The potential value of urine Fn still needs to be validated in large, multi-center, and prospective studies.Electronic supplementary materialThe online version of this article (10.1186/s12957-018-1358-x) contains supplementary material, which is available to authorized users.

show abstract

“…Once the balance breaks, it may lead to various neurodegenerative diseases with a fundamental pathological feature of cell death, such as strokes with a high number of neurons dying by necrosis (Tian et al, 2019;Zhou et al, 2020). Some researchers have Karamitopoulou et al, 2007;Farnebo et al, 2011;Omori et al, 2011;Sen et al, 2015;Heng et al, 2016;Bani-Ahmad et al, 2018;Chen et al, 2019;Henrich et al, 2019;Moledina et al, 2019;Schiffmann et al, 2019 Prognostic Bcl-2, Bax, p53, Fas, FasL, caspase-2, caspase-3, caspase-7, caspase-8, caspase-9, TNF-α, DNA fragmentation, Bak, Bok, Bim, PUMA, PMAIP1, MCL1, BCL2L10, TRAIL, TRAIL-R1/2/3, c-FLIP, IAPs Feng et al, 2018;Huang K.H. et al, 2018 Necroptosis Diagnostic NLRP3, AUNIP, RIPK1/3 He et al, 2016;Lee et al, 2016;Yang Z. et al, 2019 Prognostic NLRP3, MLKL, RIPK1/3, TLR3/TICAM1, AURKA Yuan et al, 2015;Yao et al, 2017;Conev et al, 2019;Soleymani Fard et al, 2019;Sun et al, 2019;Malhotra et al, 2020 Autophagy Diagnostic LC3, Na+/K+-ATPase, mTOR Mijatovic et al, 2012;Mete et al, 2018;Sui et al, 2018 Prognostic LC3, ATG, BECN1, Na + /K + -ATPase, AMPK, mTOR Cao et al, 2016;Cheng et al, 2016;Schläfli et al, 2016;Gajate et al, 2018;Guo et al, 2019 Ferroptosis Diagnostic GPX4, ALOX15, SLC7A11, BAP1, HSP90, HSPB1, FANCD2, TP53 Kamal et al, 2004;Guerriero et al, 2015;Saif et al, 2016;Hui et al, 2017;…”

Section: Rcds Detection In Clinic Usagementioning

confidence: 99%

Guidelines for Regulated Cell Death Assays: A Systematic Summary, A Categorical Comparison, A Prospective

Lin

et al. 2021

Front. Cell Dev. Biol.

View full text Add to dashboard Cite

Over the past few years, the field of regulated cell death continues to expand and novel mechanisms that orchestrate multiple regulated cell death pathways are being unveiled. Meanwhile, researchers are focused on targeting these regulated pathways which are closely associated with various diseases for diagnosis, treatment, and prognosis. However, the complexity of the mechanisms and the difficulties of distinguishing among various regulated types of cell death make it harder to carry out the work and delay its progression. Here, we provide a systematic guideline for the fundamental detection and distinction of the major regulated cell death pathways following morphological, biochemical, and functional perspectives. Moreover, a comprehensive evaluation of different assay methods is critically reviewed, helping researchers to make a reliable selection from among the cell death assays. Also, we highlight the recent events that have demonstrated some novel regulated cell death processes, including newly reported biomarkers (e.g., non-coding RNA, exosomes, and proteins) and detection techniques.

show abstract

Diagnostic Performance of Fas Ligand mRNA Expression for Acute Rejection after Kidney Transplantation: A Systematic Review and Meta-Analysis

Cited by 4 publications

References 51 publications

Lower Circulating Cytotoxic T-Cell Frequency and Higher Intragraft Granzyme-B Expression Are Associated with Inflammatory Interstitial Fibrosis and Tubular Atrophy in Renal Allograft Recipients

Lower Circulating Cytotoxic T-Cell Frequency and Higher Intragraft Granzyme-B Expression Are Associated with Inflammatory Interstitial Fibrosis and Tubular Atrophy in Renal Allograft Recipients

Effectiveness of urine fibronectin as a non-invasive diagnostic biomarker in bladder cancer patients: a systematic review and meta-analysis

Guidelines for Regulated Cell Death Assays: A Systematic Summary, A Categorical Comparison, A Prospective

Contact Info

Product

Resources

About